The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Worth pointing out that patients in the clinicle trial are getting treatment unless they are given the placebo.
Worth pointing out that patients in the clinicle trial are getting treatment unless they are given the placebo.
"The board of Synairgen are probably just as frustrated as us shareholders at the red tape and the obstacles."
Appearance of a super drug at this moment in time would seriously undermine the vaccination effort (especially in US).
I have no doubt that all relevant players know the potential of SNG001 and that the treatment works. All those denied access to this treatment, due to prolonged 'trials' are simple collateral damage. (IMO of course)
It might be an useful exercise to compare the options awarded to the highly competent, hardworking and pro-active Synairgen team, with those awarded to some boards of AIM companies, who have added zero value as far as shareholders are concerned. You may well be surprised to discover how modest the Synairgen awards are by comparison.
CG77, why would there be a delay in an RNS regarding the issue of options?
Do you think a publicly traded company issuing options is unusual?
You're really scraping the barrel now
CG77 is a standard Troll, probably Joker ignore his vile rhetoric
I see there's no delays in issuing themselves options at 1p and getting the rns out.
The board of Synairgen are probably just as frustrated as us shareholders at the red tape and the obstacles.
The missing links is a LSE problem. They get stripped out on here.
You need to go to either the company's website or to the actual London Stock Exchange website to get the proper RNS.
I have the London Stock Exchange set to email me when an RNS is issued so I can pick up the full document from the link in the email.
As you said Mike, there was a lot of content in that Q&A; it felt confident, I felt safe with that format, and I liked what I heard. RM was ok, I'd far rather he spend his time on the science, trials, and getting SNG to market than practicing presentation - he did what I'd expect as a shareholder, gave me confidence that all was going to plan.
The only thing wrong was presentational style and I’ll take facts and science over that any day of the year.
Market appears not to have any false hope about an AGM which is a legal "boring" requirement and where the Chairman has no option but to talk well about the business and merely repeat what was in the Annual Report. If the Chairman has something really new to say, it has to be via an RNS
I couldn't disagree more, this board are definitely not useless. It was a restatement of what is going on, they're 100% focused on getting this drug to market worldwide and extending its use to treat other respiratory illnesses. They've so many positive things going on, just needs shareholders to be patient. Activ2 news could drop anytime and India/South America will drive P3 numbers very quickly. They could also drop long Covid news fairly shortly.
Buy and Hold, sit on your hands.
CG the price dropped because he refused to give an update on the leak.. nothing to do with an update, that has actually for the first time has clarified a lot of questions!
They can't just magic an RNS out of thin air FFS. Either they have new market sensitive information or they haven't.
But still invested in a bunch of pigs??
Pi's not pigs
Can't brink myself to listen to the same old triple.
We should have had an rns in the run up to get everyone in a good mood. This bod are useless and keep pedling the same old news. What I want 2 know is why is sng still on anctiv2 if still not progressed to p3 ? When do we expect a move to p3 ? How's are own p3 going ,m
Looks like the market agrees will me ! Every time this bunch of clowns speak the sp falls. They would help the pigs more if they just stayed at home !@